Media Center

Press Releases

more...

May 19, 2010
The Collaborative Future: A Case Study
In our February 2010 special report, “The Time Has Come for Automation in Bioprocessing,” one theme that made itself clear was the need for vendors, biopharmaceutical companies, and sometimes even regulators to work together toward the goal of better, faster, and cheaper product development through (among other things) automation technologies. Martin Rhiel of Novaris cell and process R&D told us, “It would be really nice to just buy it and implement it, but this doesn’t always work. . . . Nowadays, the FDA is working together with pharmaceutical companies in implementing new technologies.”

Source: BioProcess International
May 15, 2010
Accelerating Small Molecule Research
While the 21st century has witnessed great strides in the life science research tools industry, it has also witnessed a simultaneous decline in productivity in the pharmaceutical industry, to the extent that small molecule R&D, on average, is currently a loss-making exercise. The problem of declining return on investment (ROI) is exacerbated by generic erosion, increased scrutiny from the FDA on the issue of drug safety, price controls and pressure from pending healthcare reform legislation, and increased hurdles for safety and/or efficacy in the new era of comparative effectiveness (CE)...

Source: Genetic Engineering Biotechnology News (GEN)

more...